Market Cap$22.92B
P/E17.81x
PEG Ratio10.82
Div yield—
Beta0.79
INCY Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)5.84%
Price vs S&P 500 (4W)-7.96%
PEG Ratio10.82
VGM Score66.27
P/E Ratio (Annual)17.81x
INCY Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $2.15 | $3.09 | +43.95%(+$0.94) | |
| Q1 2026 | $1.34 | $1.81 | +35.12%(+$0.47) | |
| Q4 2025 | $1.92 | $1.80 | -6.08%(-$0.12) | |
| Q3 2025 | $1.64 | $2.26 | +38.04%(+$0.62) | |
| Q2 2025 | $1.47 | $1.57 | +6.59%(+$0.10) |
INCY Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.66
3.76
3.76
3.74
Industry Peers — R&D — Physical Sciences(17)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|---|---|---|
INCYIncyte Genomics Inc | C | B | B | 17.8x | 29.6% | 14.0% | — | $113.07 |
| IQVIQVIA Holdings Inc. | D | C | A | 32.3x | 21.9% | 7.5% | — | $266.90 |
| MEDPMedpace Holdings, Inc. Common Stock | F | B | B | 38.3x | 110.2% | 22.3% | — | $618.47 |
| CRLCharles River Laboratories International, Inc. | F | D | A | — | -7.7% | 6.5% | — | $300.15 |
| ICLRIcon Plc | C | C | B | 57.3x | 0.8% | 24.1% | — | $170.18 |
| ABSIAbsci Corporation Common Stock | F | F | B | — | -59.2% | -10.1% | — | $8.25 |
| OABIOmniAb, Inc. Common Stock | F | B | A | — | -16.6% | -4.3% | — | $4.59 |
| NRCNRC Health Common Stock | D | D | B | 38.4x | 48.5% | 0.6% | 1.2% | $20.15 |
| MXCTMaxCyte, Inc. Common Stock | C | D | B | — | -21.0% | 4.8% | — | $1.30 |
| IBACIB Acquisition Corp. Common Stock | — | D | C | 15.9x | -3.7% | — | — | $10.86 |
| ONMDOneMedNet Corp Class A Common Stock | D | A | D | — | -6.8% | — | — | $4.51 |
About Incyte Genomics Inc
Incyte is a biopharmaceutical company specializing in small-molecule therapies for oncology, rheumatology, and dermatology. Jakafi, its flagship product for rare blood cancers and graft versus host disease, is co-developed with Novartis. The company markets multiple approved drugs including Olumiant (with Eli Lilly), Iclusig, Pemazyre, Tabrecta, Monjuvi, and the dermatology product Opzelura for atopic dermatitis and vitiligo. Its pipeline includes additional oncology and dermatology candidates.